Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Change in Cash (2020 - 2025)

Historic Change in Cash for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to -$28.6 million.

  • 4D Molecular Therapeutics' Change in Cash fell 177936.93% to -$28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.0 million, marking a year-over-year decrease of 5768.73%. This contributed to the annual value of -$99.8 million for FY2024, which is 15070.82% down from last year.
  • According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Change in Cash is -$28.6 million, which was down 177936.93% from -$56.4 million recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Change in Cash peaked at $157.7 million during Q2 2023, and registered a low of -$152.8 million during Q3 2021.
  • For the 5-year period, 4D Molecular Therapeutics' Change in Cash averaged around -$12.0 million, with its median value being -$16.1 million (2021).
  • As far as peak fluctuations go, 4D Molecular Therapeutics' Change in Cash soared by 85910.14% in 2023, and later crashed by 177936.93% in 2025.
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Change in Cash stood at $62.0 million in 2021, then tumbled by 190.22% to -$55.9 million in 2022, then soared by 52.51% to -$26.6 million in 2023, then crashed by 43.78% to -$38.2 million in 2024, then rose by 25.13% to -$28.6 million in 2025.
  • Its Change in Cash was -$28.6 million in Q3 2025, compared to -$56.4 million in Q2 2025 and -$15.8 million in Q1 2025.